Business Context and Reporting Period
Company: Rayonier Advanced Materials Inc. (RYAM)
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2024
Reporting Period: Event-based filing regarding capital raising activities for the RYAM BioNova SAS subsidiary.
Key Financial Metrics and Capital Structure
This filing details a combined capital raise of EUR 67 million to fund the company's biomaterials strategy, structured as follows:
- Debt Financing: EUR 37 million in secured term loans via a Senior Credit Loan Agreement.
- Equity Financing: Up to EUR 30 million in preferred shares from SWEN Impact Fund for Transition 3.
- Debt Terms:
- Tranche A: EUR 27.75 million; Floating rate (EURIBOR + 2.00%); Quarterly repayments starting Feb 2027; Maturity Nov 2031.
- Tranche B: EUR 9.25 million; Floating rate (EURIBOR + 2.50%); Balloon repayment; Maturity Nov 2032.
- Equity Terms:
- Ownership: 20% stake in RYAM BioNova SAS.
- Funding Schedule: EUR 15 million at closing; remaining EUR 15 million contingent on project milestones.
- Investor Returns: Minimum 16% Internal Rate of Return (IRR) and 2x investment multiple; preferential dividend rights.
Note: This filing does not provide consolidated revenue, profit, cash flow, or margin data for the parent company.
Material Changes and Transactions
The primary material change is the entry into two definitive agreements on November 12, 2024:
- Senior Credit Loan Agreement: Established a new EUR 37 million credit facility with Crédit Lyonnais, Arkéa Banque Entreprises et Institutionnels, and BNP Paribas to support RYAM BioNova SAS operations.
- Shareholder Agreement: Secured strategic equity investment from SWEN Impact Fund for Transition 3, altering the capital structure of the RYAM BioNova SAS subsidiary.
Outlook, Management Commentary, and Risks
Management Commentary: The capital raise is explicitly designated to invest in the company's "Biomaterials Strategy."
Governance: A supervisory committee has been established for RYAM BioNova SAS, comprising three RYAM-appointed members and one SWEN-appointed member to oversee strategic direction.
Risks and Contingencies:
- Performance Metrics: Interest margins on the debt facility are subject to adjustment based on financial performance metrics.
- Contingent Funding: The second tranche of the equity investment (EUR 15 million) is contingent upon the achievement of specific project milestones.
- Exit Rights: The equity investor holds specific exit rights and preferential dividend distribution rights.
Key Facts for Investor Verification
- Verify the specific "financial performance metrics" that trigger interest rate adjustments on the EUR 37 million debt facility.
- Confirm the definition and timeline of the "key project milestones" required to unlock the remaining EUR 15 million equity funding.
- Review the full text of the Credit Agreement and Shareholder Agreement (exhibits to the 2024 Form 10-K) for covenants and exit clauses.
- Assess the impact of the 20% dilution and preferential dividend rights on the future cash flows available to common shareholders of RYAM BioNova SAS.